Prana Biotech +15% on favorable PBT434 pre-clinical results

01:52 EDT 4 Jul 2017 | Topix

Prana Biotechnology jumps as much as 25% after disclosing that the article "The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease" was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications . Prana says the article includes pre-clinical data that shows its PBT434 drug candidate lowers levels of alpha-synuclein, a brain protein widely believed to be involved in the pathogenesis of Parkinson's disease and related disorders.

Original Article: Prana Biotech +15% on favorable PBT434 pre-clinical results


More From BioPortfolio on "Prana Biotech +15% on favorable PBT434 pre-clinical results"

Quick Search


Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...